ArticleMolecular biotechnology2026
The Role of Yes-Associated Protein in Autophagy and Tumor Progression in Gastric Cancer.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Yes-associated protein (YAP) is a key regulator in the pathogenesis of gastric cancer (GC), yet its role in modulating autophagy remains unclear. This study investigated the effects of YAP modulation on autophagy and tumor progression using the SNU-484 and MKN-74 gastric cancer cell lines. YAP overexpression led to increased B-cell lymphoma-2 (BCL-2) transcription, reducing autophagy and enhancing cell survival, while YAP knockdown resulted in elevated autophagic activity. In vivo experiments with nude mice confirmed that YAP overexpression promotes tumor growth, whereas YAP silencing inhibits it. Further analysis revealed that YAP directly binds to the BCL-2 promoter, driving its transcription and thereby inhibiting autophagy-induced cell death. Importantly, silencing BCL-2 mitigated the autophagy inhibition caused by YAP without affecting YAP expression itself. These findings indicate that YAP, by upregulating BCL-2, suppresses autophagy and contributes to gastric cancer progression, suggesting a potential therapeutic strategy targeting the YAP-BCL-2 axis in GC treatment.
Indexed as
Identifiers
39976859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.